Sep 29, 2022 / 11:00AM GMT
Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director
Good afternoon from London, and many thanks for joining us today for Allergy Therapeutics' preliminary results for the year ended 30th of June 2022. It is lovely to be joined by those in the room after past year of virtual meetings, and a warm welcome also to those joining us online.
With me here today, we have Nick Wykeman, Allergy Therapeutics' Chief Financial Officer; and our Head of Business Innovation, Alan Bullimore.
And before we begin proceedings, I'll quickly bring your attention to the standard disclaimer slide, which is included in this presentation for completeness. So let go through the disclaimer, and let us start the presentation. On Slide number 4, we are seeing here the main highlights -- financial highlights. Reported sales of GBP 72.8 million, reflecting planned streamlining, and operating profit pre-R&D of GBP 3.4 million and a net loss of GBP 13.8 million, ending the year with a cash balance of GBP 20.5 million. On the operational side, we are mainly focused on the clinical developments. We
Full Year 2022 Allergy Therapeutics PLC Earnings Call Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers